Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptional down-regulation of the TGFB2 gene by multiple Fra-1-bound enhancers showing different molecular and functional features in a Triple Negative Cancer (ATAC-Seq)

ABSTRACT: Transcriptional down-regulation of the TGFB2 gene by multiple Fra-1-bound enhancers showing different molecular and functional features in a Triple Negative Cancer (ATAC-Seq)

PROVIDER: PRJNA859924 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR20300491_1.fastq.gz	Fastqsanger.gz
	SRR20300491_2.fastq.gz	Fastqsanger.gz
	SRR20300492_1.fastq.gz	Fastqsanger.gz
	SRR20300492_2.fastq.gz	Fastqsanger.gz
	SRR20300493_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Transcriptional down-regulation of the TGFB2 gene by multiple Fra-1-bound enhancers showing different molecular and functional features in a Triple Negative Cancer

Project description:Transcriptional down-regulation of the TGFB2 gene by multiple Fra-1-bound enhancers showing different molecular and functional features in a Triple Negative Cancer

| PRJNA859921 | ENA

Transcriptional down-regulation of the TGFB2 gene by multiple Fra-1-bound enhancers showing different molecular and functional features in a Triple Negative Cancer (ATAC-Seq)

Project description:mapping of chromatin accessibility in MDA-MB-231 cells in presence and absence of Fra-1 by ATAC-seq experiments

2023-07-25 | GSE208441 | GEO

Transcriptional down-regulation of the TGFB2 gene by multiple Fra-1-bound enhancers showing different molecular and functional features in a Triple Negative Cancer (ChIP-Seq)

Project description:Transcriptional down-regulation of the TGFB2 gene by multiple Fra-1-bound enhancers showing different molecular and functional features in a Triple Negative Cancer (ChIP-Seq)

| PRJNA859923 | ENA

Transcriptional down-regulation of the TGFB2 gene by multiple Fra-1-bound enhancers showing different molecular and functional features in a Triple Negative Cancer

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-07-25 | GSE208443 | GEO

Transcriptional down-regulation of the TGFB2 gene by multiple Fra-1-bound enhancers showing different molecular and functional features in a Triple Negative Cancer (ChIP-Seq)

Project description:genome-wide mapping of H3K36me3 histone mark in the MDA-MB-231 cell line

2023-07-25 | GSE208442 | GEO

Comparative analysis of gene expression in Fra-1+/+ and Fra-1-/- mice lung

2014-05-22 | GSE43695 | GEO

Identification of Fra-1 and/or Fra-2 regulated genes in MDA-MB231 cells

Project description:In the paper "Fra-1 regulates its target genes via binding to remote enhancers without exerting major control on chromatin architecture in triple negative breast cancers" by Bejjani et al., we identified Fra-1 and/or Fra-2 target genes in MDA-MB-231 cells. si RNA against Fra-1 and against Fra-2 were transfected in MDA-MB-231 cells either independenlty or simultaneously to identify genes regulated specifically by Fra-1 or Fra-2 and genes regulated redundantly or complementarily by Fra-1 and Fra-2 total RNA were purified and biotinylated sense-strand cDNA were produced. cDNA targets were used to probe Affymetrix GeneChip Human Gene 2.0 ST arrays

2021-02-23 | GSE146823 | GEO

Blocking Fra-1 sensitizes triple-negative breast cancer to olaparib

Project description:Fra-1 (FOSL1) is overexpressed in triple-negative breast cancer (TNBC). Fra-1 is a member of the activator protein 1 (AP-1) transcription factor complex, which plays crucial roles in tumor progression and treatment resistance. We have previously identified 118 proteins that interact with endogenous chromatin-bound Fra-1 in TNBC cells in a large screen, and these included PARP1(Poly (ADP-ribose) polymerase 1). PARP1 inhibitor olaparib is currently in clinical use for treatment of BRCA-mutated TNBC breast cancer. Here, we demonstrate that this interaction impacts the efficacy of olaparib treatment. We corroborate that PARP1 interacts with Fra-1, and we show that PARP1 downregulates Fra-1 and consequently reduces AP-1 transcriptional activity. Inhibition of PARP1, on the other hand, increases Fra-1 levels and enhances its transcriptional activity, which in turn can increase treatment resistance. However, by inhibiting Fra-1, we found that TNBC cells became sensitized to olaparib treatment. We compared Fra-1 chromatin binding sites with the Fra-1 and PARP1 regulated transcriptomes, and found that a large fraction of PARP1-regulated genes was dependent on Fra-1. We further show that PARP1 protein levels significantly correlate with Fra-1 in clinical breast cancer tumors, and we identify that high PARP1 expression is indicative of a poor clinical outcome in breast cancer patients overall, but not in basal-like tumors. In conclusion, by exploring the functionality of the Fra-1 and PARP1 interaction, we propose that targeting Fra-1 could serve as a therapeutic approach to improve olaparib treatment outcome for TNBC patients.

2022-04-21 | GSE149621 | GEO

Comparative analysis of gene expression in Fra-1+/+ and Fra-1-/- mice lung

Project description:We hypothesized that gene expression in lungs of Fra-1+/+ and Fra-1-/- mice are divergent thus contributing fibrosis. More specifically, Fra-1-/- mice are increased susceptible to fibrosis. In order to test these hypotheses at the gene expression level, we utilized microarray analysis to examine transcriptional differences between Fra-1+/+ and Fra-1-/- mice at early time point. This study utilizes microarray analysis to test these hypotheses. 5 days PBS and bleomycin treated lung samples from both Fra-1+/+ and Fra-1-/- mice were used. RNA was isolated and used for global gene expression profiling (Affymetrix MoGene 1.0ST v1 Array). The raw probe signal intensities were quantile normalized over all samples, summarized with the robust multi-array average (RMA) algorithm and log2 transformed with a median polish, using the Affymetrix Power Tools. We considered a transcript cluster (gene-level) to be reliably expressed in a sample if the Affymetrix implemented DABG (detection above ground) p-value was less than 0.05. We used local-pooled-error (LPE) estimates and robust statistical tests for evaluating significance of each gene's differential expression in a comparison.

2014-05-22 | E-GEOD-43695 | biostudies-arrayexpress

Transcript profiling in peritoneal macrophages from wildtype, Fra-1ΔMxCre or Fra-2ΔLysMCre mice

Project description:The polarization and activation of macrophages are controlled synergistically by transcription factors such as NF-κB and AP-1 transcription factor members. Surprisingly, little is known about the role of the Fra proteins, both members of the AP-1 transcription factor family, in macrophage activity. To determine the full profile of Fra network, microarray RNA expression analysis using Agilent Technologies platform was performed in wild-type, Fra-1ΔMxCre or Fra-2ΔLysMCre macrophages.

2021-05-17 | GSE128787 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data